Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Major Program
Supportive Care and Symptom Management
Research Group
Community Oncology and Prevention Trials
M.D. Anderson Cancer Center
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03743649
This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care. Haloperidol and lorazepam may help in controlling symptoms of agitated delirium in patients with cancer and may lessen any distress that their caregivers may be experiencing.
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
David Hui

See list of participating sites